A detailed history of Brewin Dolphin LTD transactions in Biogen Inc. stock. As of the latest transaction made, Brewin Dolphin LTD holds 1,668 shares of BIIB stock, worth $248,565. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,668
Previous 1,602 4.12%
Holding current value
$248,565
Previous $337,000 0.89%
% of portfolio
0.02%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Nov 14, 2022

BUY
$187.54 - $223.02 $12,377 - $14,719
66 Added 4.12%
1,668 $340,000
Q4 2021

Nov 14, 2022

BUY
$223.92 - $287.77 $358,719 - $461,007
1,602 New
1,602 $384,000
Q2 2021

Nov 09, 2023

SELL
$259.0 - $414.71 $10,360 - $16,588
-40 Reduced 1.6%
2,464 $853 Million
Q1 2021

Nov 09, 2023

BUY
$242.95 - $284.63 $86,733 - $101,612
357 Added 16.63%
2,504 $700 Million
Q4 2020

Nov 09, 2023

BUY
$236.26 - $355.63 $51,032 - $76,816
216 Added 11.19%
2,147 $526 Million
Q3 2020

Nov 09, 2023

SELL
$264.77 - $305.71 $5,295 - $6,114
-20 Reduced 1.03%
1,931 $548 Million
Q2 2020

Nov 09, 2023

SELL
$258.66 - $342.55 $119,242 - $157,915
-461 Reduced 19.11%
1,951 $522 Million
Q1 2020

Nov 09, 2023

BUY
$268.85 - $341.04 $178,247 - $226,109
663 Added 37.91%
2,412 $763 Million
Q4 2019

Nov 09, 2023

SELL
$220.06 - $304.07 $7,482 - $10,338
-34 Reduced 1.91%
1,749 $519 Million
Q3 2019

Nov 09, 2023

SELL
$217.44 - $243.88 $5,436 - $6,097
-25 Reduced 1.38%
1,783 $415 Million
Q3 2018

Nov 09, 2023

SELL
$293.51 - $383.83 $14,675 - $19,191
-50 Reduced 2.69%
1,808 $639 Million
Q2 2018

Nov 09, 2023

SELL
$257.52 - $306.91 $14,163 - $16,880
-55 Reduced 2.88%
1,858 $539 Million
Q1 2018

Nov 09, 2023

SELL
$260.13 - $367.91 $28,874 - $40,838
-111 Reduced 5.48%
1,913 $524 Million
Q4 2017

Nov 09, 2023

BUY
$307.64 - $344.58 $19,381 - $21,708
63 Added 3.21%
2,024 $645 Million
Q3 2017

Nov 09, 2023

BUY
$281.15 - $329.69 $82,376 - $96,599
293
1,961 $614 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Brewin Dolphin LTD Portfolio

Follow Brewin Dolphin LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

News

Stay updated on Brewin Dolphin LTD with notifications on news.